

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM459744

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	MERGER		
<b>EFFECTIVE DATE:</b>	11/30/2014		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Neoplasia Press, Inc.		11/20/2014	Corporation: MICHIGAN
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Elsevier Inc.		
<b>Street Address:</b>	360 Park Avenue South		
<b>City:</b>	New York		
<b>State/Country:</b>	NEW YORK		
<b>Postal Code:</b>	10010		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	2546357	JOURNALSOFT	
<b>Registration Number:</b>	3376128	NEOPLASIA	
<b>Registration Number:</b>	4432358	TRANSLATIONAL ONCOLOGY	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8669602609		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	9378651214		
<b>Email:</b>	Trademarks@RELX.com		
<b>Correspondent Name:</b>	Shari A. Townsend		
<b>Address Line 1:</b>	9443 Springboro Pike		
<b>Address Line 4:</b>	Miamisburg, OHIO 45342		
<b>NAME OF SUBMITTER:</b>	Shari A. Townsend		
<b>SIGNATURE:</b>	/Shari A. Townsend/		
<b>DATE SIGNED:</b>	01/29/2018		
<b>Total Attachments: 3</b>			
source=Merger - Neoplasia Press, Inc. (MI corp.) into Elsevier Inc. (DE corp.) - 11-30-14#page1.tif			
source=Merger - Neoplasia Press, Inc. (MI corp.) into Elsevier Inc. (DE corp.) - 11-30-14#page2.tif			
source=Merger - Neoplasia Press, Inc. (MI corp.) into Elsevier Inc. (DE corp.) - 11-30-14#page3.tif			

OP \$90.00 2546357

**MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS**

**FILING ENDORSEMENT**

*This is to Certify that the CERTIFICATE OF MERGER*

*for*

**NEOPLASIA PRESS, INC.**

**ID NUMBER: 533569**

*received by facsimile transmission on November 20, 2014 is hereby endorsed.*

*Filed on November 20, 2014 by the Administrator.*

*This document is effective on the date filed, unless a subsequent effective date within 90 days after received date is stated in the document.*

**Effective Date: November 30, 2014**



*Sent by Facsimile Transmission*

*In testimony whereof, I have hereunto set my hand and affixed the Seal of the Department, in the City of Lansing, this 20th day of November, 2014.*

**Alan J. Schefke, Director  
Corporations, Securities & Commercial Licensing Bureau**

**MICHIGAN DEPARTMENT OF LICENSING AND REGULATORY AFFAIRS  
CORPORATIONS, SECURITIES & COMMERCIAL LICENSING BUREAU**

Date Received

This document is effective on the date filed, unless a subsequent effective date within 90 days after received date is stated in the document.

Name

Address

City

State

ZIP Code

EFFECTIVE DATE: **11-30-2014**

Expiration date for new assumed names: December 31,

Expiration date for transferred assumed names appear in Item 6

Document will be returned to the name and address you enter above. If left blank, document will be returned to the registered office.

**CERTIFICATE OF MERGER**

**Cross Entity Merger for use by Profit Corporations, Limited Liability Companies and Limited Partnerships**

Pursuant to the provisions of Act 284, Public Acts of 1972 (profit corporations), Act 23, Public Acts of 1993 (limited liability companies) and Act 213, Public Acts of 1982 (limited partnerships), the undersigned entities execute the following Certificate of Merger:

1. The Plan of Merger (Consolidation) is as follows:

a. The name of each constituent entity and its identification number is:

Neoplasia Press, Inc.

533569

Elsevier Inc.

60404G

b. The name of the surviving (new) entity and its identification number is:

Elsevier Inc.

60404G

Corporations and Limited Liability Companies provide the street address of the survivor's principal place of business:  
360 Park Avenue South, New York, NY 10010

2. (Complete only if an effective date is desired other than the date of filing. The date must be no more than 90 days after the receipt of this document in this office.)

The merger (consolidation) shall be effective on the 30 day of November, 2014.

**Complete for Profit Corporations Only**

For each constituent stock corporation, state:

Name of corporation	Designation and number of outstanding shares in each class or series	Indicate class or series of shares entitled to vote	Indicate class or series entitled to vote as a class
Elsevier Inc.	100	Common	
Neoplasia Press, Inc.	1000	Common	

If the number of shares is subject to change prior to the effective date of the merger or consolidation, the manner in which the change may occur is as follows:

The manner and basis of converting shares are as follows:

All issued/outstanding shares of stock of Neoplasia Press, Inc. shall be canceled & cease to exist. Each issued & outstanding share of common stock (\$.01 par/share), of Elsevier Inc. shall continue to represent 1 share of common stock (.01 par/share) of Elsevier Inc.

The amendments to the Articles, or a restatement of the Articles, of the surviving corporation to be effected by the merger are as follows:

none

The Plan of Merger will be furnished by the surviving profit corporation, on request and without cost, to any shareholder of any constituent profit corporation.

The merger is permitted by the state or country under whose law it is incorporated and each foreign corporation has complied with that law in effecting the merger.

(Complete either Section (a) or (b) for each corporation)

a) The Plan of Merger was approved by unanimous consent of the incorporators of \_\_\_\_\_, a Michigan corporation which has not commenced business, has not issued any shares, and has not elected a Board of Directors.

\_\_\_\_\_  
(Signature of Incorporator)

\_\_\_\_\_  
(Type or Print Name)

\_\_\_\_\_  
(Signature of Incorporator)

\_\_\_\_\_  
(Type or Print Name)

\_\_\_\_\_  
(Signature of Incorporator)

\_\_\_\_\_  
(Type or Print Name)

\_\_\_\_\_  
(Signature of Incorporator)

\_\_\_\_\_  
(Type or Print Name)

b) The plan of merger was approved by:

the Board of Directors of \_\_\_\_\_, the surviving Michigan corporation, without approval of the shareholders in accordance with Section 703a of the Act.

the Board of Directors and the shareholders of the following Michigan corporation(s) in accordance with Section 703a of the Act.

Neoplasia Press, Inc.

By Renee Simonton  
(Signature of Authorized Officer or Agent)

Renee Simonton, Vice President  
(Type or Print Name)

Neoplasia Press, Inc.  
(Name of Corporation)

By Mark Seeley  
(Signature of Authorized Officer or Agent)

Mark Seeley, Senior Vice President  
(Type or Print Name)

Elsevier Inc.  
(Name of Corporation)